Check Claims Before You Publish

Visual summary (metrics & topical footprint)

Interpretation: bibliometrics place Vázquez‑Larios as an active contributor (≈9–10 papers) with modest citation impact (h ≈5–6) concentrated in infectious disease surveillance, AMR networks (INVIFAR), and recent genomic analyses of clinically relevant gram‑negative bacteria.

Research focus & strengths (evidence-backed)

• Surveillance leadership and high-throughput datasets: Multiple INVIFAR network reports (PLoS ONE 2025; Pathogens 2023) and national surveillance papers contribute large multi-centre isolate collections and standardized AMR phenotype/genotype reporting, improving epidemiological resolution in Mexico INVIFAR 2024 surveillance (PLoS ONE 2025)
• Genomics + phenotyping integration: The 2026 Microbial Genomics study merges Illumina WGS, resistome annotation, MLST, and targeted expression assays across 136 CRPA isolates — enabling lineage‑level inference about non‑carbapenemase mechanisms (oprD disruption; efflux overexpression) Microbial Genomics 2026 CRPA study
• Practical bioinformatics use: Co‑authorship on method comparisons (EPISEQ CS vs other pipelines) shows practical emphasis on reproducible genomic pipelines for resistome/virulome analyses (J. Global Antimicrobial Resistance 2023) EPISEQ CS comparative WGS paper (JGAR 2023)

Limitations, blindspots & potential biases

• Many publications are multi‑author, network surveillance outputs; author appears primarily as a middle author in several large consortia — difficult to attribute leadership vs contributing roles without author contribution statements.
• Surveillance studies risk sampling and reporting biases (non-random clinical sampling, variable lab practices) — acknowledged in the CRPA paper and INVIFAR reports; expression experiments were small (n≈18) limiting generalizability Microbial Genomics 2026 CRPA study
• Some work relies on vendor platforms (EPISEQ CS) — useful for applied surveillance but requires care to avoid platform-induced artefacts; comparative validation reduces but does not eliminate platform bias EPISEQ CS comparative WGS paper (JGAR 2023)

Concrete evaluation (what the evidence shows)

1. Productive contributor to national AMR surveillance networks — publications deliver large datasets and open data (PRJNA1211528) useful for downstream analyses Microbial Genomics 2026 CRPA study
2. Methodologically competent: shows familiarity with WGS pipelines, resistome databases, phylogenomics, and phenotypic assays; publications use accepted tools and cross-validation steps (e.g., ABRicate, CARD/ResFinder) Microbial Genomics 2026 CRPA study
3. Impact is pragmatic and regionally important; citation counts are modest but concentrated on surveillance/AMR topics that influence local policy and laboratory practice (INVIFAR outputs; PLoS ONE 2021 & 2025) INFIVAR network AMR baseline (PLoS ONE 2021)

Actionable recommendations to strengthen author's scientific profile

• Lead authorship on integrative genomics papers (clearly stated contributions) to increase attributable scientific credit and clarity of role.
• Increase sample sizes for expression/functional assays and include AmpC/other mechanisms to close current mechanistic blindspots (as acknowledged in the 2026 paper) Microbial Genomics 2026 CRPA study
• Publish explicit author contribution statements and (when possible) link genomic findings to clinical outcomes to boost translational value.

Where additional evidence would shift conclusions

Stronger inference about lineage‑specific causation would require: larger expression/functional validation (complementation, knockouts), uniform antibiotic exposure assays, and linkage to patient outcomes; absence of these would weaken claims that phylogeny drives specific resistance adaptations (the CRPA paper lists these falsification criteria) Microbial Genomics 2026 CRPA study